The Pharmacy Times® Retail Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to retail, community, and independent pharmacists.
August 4th 2025
In the SURPASS-CVOT clinical trial, tirzepatide was non-inferior to dulaglutide in a composite score of cardiovascular outcomes in patients with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD).
Teva and Immuneering Announce Teva's Purchase of 51% Equity Share of Genomic-Analysis Company
August 3rd 2015Teva Pharmaceutical Industries Ltd. and Immuneering Corporation announced that the companies have entered into an agreement in which Teva will purchase a 51% equity share of the company.
Read More